Comparison of elderly and young onset rheumatoid arthritis

Comparison of elderly and young onset rheumatoid arthritis

Objective: To describe demographic, clinical, paraclinical and therapeutic characteristics of elderly onset (EORA) compared to young-onset (YORA) rheumatoid arthritis. Patients and Methods: We studied 50 EORA and 100 YORA. Socio-demographic characteristics, clinical and paraclinical data of the dis...

Full description

Bibliographic Details
Main Authors:	N. Jaouad, B. Amine, I. Elbinoune, S. Rostom, R. Bahiri
Format:	Article
Language:	English
Published:	Verduci Editore 2022-12-01
Series:	Beyond Rheumatology
Subjects:	rheumatoid arthritis elderly onset young-onset disease activity life quality comorbidities disease modifying antirheumatic drugs
Online Access:	https://www.beyond-rheumatology.org/wp-content/uploads/sites/10/2022/12/e445.pdf

Similar Items

Comparison of the drug retention and reasons for discontinuation of tumor necrosis factor inhibitors and interleukin-6 inhibitors in Japanese patients with elderly-onset rheumatoid arthritis—the ANSWER cohort study
by: Sadao Jinno, et al.
Published: (2021-04-01)

Elderly-Onset Rheumatoid Arthritis: Characteristics and Treatment Options
by: Slavica Pavlov-Dolijanovic, et al.
Published: (2023-10-01)

Inflammatory profile of incident cases of late-onset compared with young-onset rheumatoid arthritis: A nested cohort study
by: Natalia Mena-Vázquez, et al.
Published: (2022-11-01)

Serum IL-40 increases in patients with rheumatoid arthritis and correlates with some clinical characteristics and comorbidities
by: Wei Wang, et al.
Published: (2024-11-01)

Characteristics of difficult-to-treat rheumatoid arthritis: a real-life study
by: C. Charoui, et al.
Published: (2024-07-01)

Elderly-onset rheumatoid arthritis — clinical findings and treatment features (systematic literature review)
by: Ye.D. Yehudina, et al.
Published: (2024-03-01)

Elderly-onset rheumatoid arthritis vs. polymyalgia rheumatica: Differences in pathogenesis
by: Jinzhi Wu, et al.
Published: (2023-01-01)

The research progress of biologics in elderly-onset rheumatoid arthritis (EORA)
by: Yujie Li, et al.
Published: (2025-01-01)

Treatment adherence to disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis
by: Xia Y, et al.
Published: (2016-05-01)

First-year drug therapy of new-onset rheumatoid and undifferentiated arthritis: a nationwide register-based study
by: Paula Muilu, et al.
Published: (2020-07-01)

GLUCOCORTICOIDS AND RHEUMATOID ARTHRITIS
by: Zhdan V. M., et al.
Published: (2020-12-01)

Targeted Therapy for Rheumatoid Arthritis in the New Era
by: WANG Jun, et al.
Published: (2025-01-01)

Difficult-to-treat rheumatoid arthritis in the clinical practice of a rheumatological hospital. First look
by: A. V. Gordeev, et al.
Published: (2022-05-01)

Association of Hydroxychloroquine Use with a Dose-Dependent Decrease in Mortality Risk in Patients with Elderly-Onset Rheumatoid Arthritis
by: Ching-Tsai Lin, et al.
Published: (2023-05-01)

Disease Activity in Disease Modifying Anti-Rheumatic Drug (DMARD) Naïve Rheumatoid Arthritis Patients in A Subset of Karachi Population
by: Dr. Mehreen Inam Illahi, et al.
Published: (2024-05-01)

Prospects for rheumatoid arthritis pharmacotherapy: New opportunities and recommendations
by: E L Nasonov
Published: (2016-12-01)

Conventional disease-modifying agents in rheumatoid arthritis – a review of their current use and role in treatment algorithms
by: Ivan Padjen, et al.
Published: (2020-12-01)

End-stage rheumatoid arthritis: specific features of patient management
by: Nadezhda Aleksandrovna Shostak, et al.
Published: (2013-06-01)

Polymyalgia Rheumatica and Seronegative Elderly-Onset Rheumatoid Arthritis: Two Different Diseases with Many Similarities
by: Ciro Manzo, et al.
Published: (2019-09-01)

Cost-minimization analysis of subcutaneous abatacept in the treatment of rheumatoid arthritis in Spain
by: R. Ariza, et al.
Published: (2014-07-01)

Early rheumatoid arthritis therapy: comparative characteristic of delagil, sulphasalazine and methotrexate
by: T S Salnikova, et al.
Published: (2003-08-01)

The tumor necrosis factor-α inhibitor golimumab in the treatment of rheumatoid arthritis
by: Natalia Vladimirovna Chichasova
Published: (2014-12-01)

Peculiarities of pharmacotherapy of patients with rheumatoid arthritis associated with interstitial lung disease
by: A. V. Gordeev, et al.
Published: (2024-02-01)

Conventional synthetic disease-modifying antirheumatic drug use by race/ethnicity and factors associated with initiating biologics in Malaysian patients with rheumatoid arthritis
by: Suad Mohammed, et al.
Published: (2019-01-01)

Rheumatoid arthritis: problems of treatment at the present stage
by: N. V. Chichasova
Published: (2018-12-01)

Childhood-onset rheumatoid arthritis at a tertiary hospital in Senegal, West Africa
by: Mounib M. Sabounji, et al.
Published: (2023-09-01)

Rheumatoid arthritis – medication dosage in chronic kidney disease
by: Kinga Maria Tyczyńska, et al.
Published: (2024-01-01)

Subjective sleep disturbances at the time of diagnosis in patients with polymyalgia rheumatica and in patients with seronegative elderly-onset rheumatoid arthritis. A pilot study
by: Ciro Manzo, et al.
Published: (2020-08-01)

Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis
by: Bernard Combe, et al.
Published: (2022-10-01)

Tocilizumab as a first-line biologic treatment in rheumatoid arthritis patients – the impact of concomitant methotrexate treatment and Rheumatic Disease Comorbidity Index on the clinical response – results from the multicenter observational ACT-POL study
by: Marcin Stajszczyk, et al.
Published: (2022-05-01)

Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study
by: Seogsong Jeong, et al.
Published: (2022-07-01)

Comparison of treatment of severe rheumatoid arthritis patients with biological agents and JAK-STAT inhibitors. An extension study
by: Małgorzata Wisłowska
Published: (2024-11-01)

STRATEGY FOR DOSE REDUCTION AND DISCONTINUATION OF BIOLOGICAL AGENTS IN RHEUMATOID ARTHRITIS REMISSION
by: M. A. Kotovskaya, et al.
Published: (2018-03-01)

iTRAQ and PRM-Based Proteomic Analysis Provides New Insights into Mechanisms of Response to Triple Therapy in Patients with Rheumatoid Arthritis
by: Chen J, et al.
Published: (2021-12-01)

A Comparison of Demographics, Disease Activity, Disability, and Treatment Among Rheumatoid Arthritis Patients with and without Osteoporosis
by: Abdulkhaliq A, et al.
Published: (2021-09-01)

Impact of Rheumatoid Arthritis on Alopecia: A Nationwide Population-Based Cohort Study in Taiwan
by: Yi-Jung Chang, et al.
Published: (2020-04-01)

COVID-19 and post-covid syndrome in patients with rheumatoid arthritis
by: E. S. Aronova, et al.
Published: (2023-08-01)

Patients With Rheumatoid Arthritis With an Inadequate Response to Disease‐Modifying Antirheumatic Drugs at a Higher Risk of Acute Coronary Syndrome
by: Chung‐Yuan Hsu, et al.
Published: (2021-04-01)

The problem of laboratory monitoring in therapy with disease-modifying antirheumatic drugs and biological agents in patients with rheumatoid arthritis
by: Yu. V. Muravyev, et al.
Published: (2018-09-01)

The clinical and pathogenetic value of Foxp3+ T regulatory cells in rheumatoid arthritis
by: A. S. Avdeeva, et al.
Published: (2016-10-01)